Modified Release Formulations Of A Bupropion Salt
First Claim
1. A modified release osmotic dosage form comprising bupropion hydrobromide present in a therapeutically effective amount, wherein said dosage form releases the bupropion hydrobromide by dispensing the bupropion hydrobromide from a core via at least one passageway in a membrane by pressure created in the core by osmosis and/or by the expansion of a swellable material which forces the bupropion hydrobromide to be dispensed from the core of the dosage form.
15 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
-
Citations
8 Claims
- 1. A modified release osmotic dosage form comprising bupropion hydrobromide present in a therapeutically effective amount, wherein said dosage form releases the bupropion hydrobromide by dispensing the bupropion hydrobromide from a core via at least one passageway in a membrane by pressure created in the core by osmosis and/or by the expansion of a swellable material which forces the bupropion hydrobromide to be dispensed from the core of the dosage form.
-
7. A modified release osmotic dosage, wherein a core comprising bupropion hydrobromide is surrounded by a semipermeable membrane which permits entry of an aqueous liquid into the core and delivery of the bupropion hydrobromide from the core to the exterior of the dosage form through at least one passageway or by a combination of osmosis and diffusion such that the dosage form exhibits an in-vitro release rate such that after 2 hours no more than 40% is released, after 4 hours 40-75% is released, after 8 hours at least 75% is released and after 16 hours at least 85% is released.
Specification